Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women

Contraception

Volumn 86, Issue 4, 2012, Pages 337-344

  Blode, Hartmut ^a   Zeun, Susan ^a   Parke, Susanne ^a   Zimmermann, Torsten ^a   Rohde, Beate ^a   Mellinger, Uwe ^a   Kunz, Michael ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Erythromycin; Estradiol valerate dienogest; Ketoconazole; Oral contraceptive; Rifampicin

Indexed keywords

CYTOCHROME P450 3A4; DIENOGEST PLUS ESTRADIOL VALERATE; ERYTHROMYCIN; KETOCONAZOLE; RIFAMPICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST DISCOMFORT; DIZZINESS; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DYSGEUSIA; ENZYME INHIBITION; FATIGUE; FEMALE; GEOMETRY; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; METRORRHAGIA; MORNING DOSAGE; MYALGIA; NORMAL HUMAN; ORAL CONTRACEPTION; PLASMA CONCENTRATION-TIME CURVE; POSTMENOPAUSE; STEADY STATE; WITHDRAWAL BLEEDING;

AGED; ANTI-INFECTIVE AGENTS; BIOTRANSFORMATION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; ERYTHROMYCIN; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTRONE; FEMALE; HUMANS; KETOCONAZOLE; MIDDLE AGED; NANDROLONE; POSTMENOPAUSE; RIFAMPIN;

EID: 84866050543     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2012.01.010     Document Type: Article

References (19)

1. S. Palacios, L. Wildt, S. Parke, A. Machlitt, T. Romer, and J. Bitzer Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a phase III trial Eur J Obstet Gynecol Reprod Biol 149 2010 57 62
2. H.J. Ahrendt, D. Makalova, S. Parke, U. Mellinger, and D. Mansour Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel Contraception 80 2009 436 444
3. S. Zeun, M. Lu, A. Uddin, B. Zeiler, D. Morrison, and H. Blode Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest Eur J Contracept Reprod Health Care 14 2009 221 232
4. W. Kuhnz, H. Blode, and H. Zimmermann Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens M. Oettel, E. Schillinger, Handbook of experimental pharmacology 2nd ed. 1999 Springer-Verlag Berlin 261 322
5. H. Yamazaki, P.M. Shaw, F.P. Guengerich, and T. Shimada Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes Chem Res Toxicol 11 1998 659 665
6. Bayer HealthCare Pharmaceuticals Natazia prescribing information. 2010 [cited 2011 01 August]; Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/022252s000lbl.pdf
7. T.D. Bjornsson, J.T. Callaghan, and H.J. Einolf The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 2003 815 832
8. G.K. Dresser, J.D. Spence, and D.G. Bailey Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 38 2000 41 57
9. S.M. Huang, J.M. Strong, and L. Zhang New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process J Clin Pharmacol 48 2008 662 670
10. Y.T. Liu, H.P. Hao, C.X. Liu, G.J. Wang, and H.G. Xie Drugs as CYP3A probes, inducers, and inhibitors Drug Metab Rev 39 2007 699 721
11. P. Barditch-Crovo, C.B. Trapnell, and E. Ette The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive Clin Pharmacol Ther 65 1999 428 438
12. B.D. Dickinson, R.D. Altman, N.H. Nielsen, and M.L. Sterling Drug interactions between oral contraceptives and antibiotics Obstet Gynecol 98 2001 853 860
13. M. LeBel, E. Masson, and E. Guilbert Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone J Clin Pharmacol 38 1998 1042 1050
14. K. Weaver, and A. Glasier Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review Contraception 59 1999 71 78
15. E. Weisberg Interactions between oral contraceptives and antifungals/antibacterials. Is contraceptive failure the result? Clin Pharmacokinet 36 1999 309 313
16. H. Zhang, D. Cui, and B. Wang Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug Clin Pharmacokinet 46 2007 133 157
17. U. Loos, E. Musch, J.C. Jensen, G. Mikus, H.K. Schwabe, and M. Eichelbaum Pharmacokinetics of oral and intravenous rifampicin during chronic administration Klin Wochenschr 63 1985 1205 1211
18. S.F. Zhou, C.C. Xue, X.Q. Yu, C. Li, and G. Wang Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 2007 687 710
19. A.E. Schindler, B. Christensen, A. Henkel, M. Oettel, and C. Moore High-dose pilot study with the novel progestogen dienogestin patients with endometriosis Gynecol Endocrinol 22 2006 9 17